Relaxin is a peptide hormone involved in connective tissue remodeling, vascular adaptation, reproductive physiology, renal blood flow regulation, and extracellular matrix organization. The hormone is best known for its role during pregnancy, where it helps prepare reproductive and cardiovascular tissues for the physiological demands of gestation and childbirth. Relaxin promotes flexibility and remodeling of ligaments, pelvic tissues, cervix, uterus, and vascular structures through coordinated effects on collagen turnover and matrix-modifying enzymes.
Relaxin also participates in regulation of blood vessel tone, nitric oxide signaling, and tissue perfusion. In the cardiovascular system, it can support vasodilation and influence endothelial function. In the kidneys, relaxin contributes to increased renal plasma flow and glomerular filtration changes associated with pregnancy adaptation. Beyond reproductive tissues, relaxin signaling influences fibroblast activity, wound remodeling, inflammatory communication, and tissue elasticity.
Relaxin is produced mainly by the corpus luteum during pregnancy and reproductive cycling. Additional production may occur in the placenta, decidua, uterus, prostate, mammary tissue, and other reproductive-associated organs depending on physiological state and sex. Relaxin belongs to the insulin-like peptide family and is synthesized as a precursor molecule that undergoes intracellular processing into mature biologically active peptide chains.
Circulating relaxin levels rise substantially during pregnancy, particularly in early gestation, when maternal tissues begin adapting to increased vascular volume, uterine expansion, and connective tissue remodeling. Production is closely associated with ovarian endocrine function and placental support systems. Relaxin receptors are widely distributed in reproductive tissues, kidneys, blood vessels, heart, connective tissue, and additional organs involved in structural adaptation.
Relaxin production is regulated by reproductive hormones, gonadotropin signaling, corpus luteum activity, pregnancy status, placental signaling, and local tissue regulatory systems. Human chorionic gonadotropin supports corpus luteum maintenance during early pregnancy and indirectly supports relaxin synthesis. Estrogen and progesterone environments may also influence receptor responsiveness and tissue sensitivity.
Relaxin acts mainly through RXFP1 receptors, activating cyclic AMP pathways, nitric oxide signaling, matrix metalloproteinase activity, and extracellular matrix remodeling systems. The hormone interacts with vascular endothelial pathways, collagen turnover mechanisms, angiogenic signaling, and inflammatory mediators involved in tissue adaptation. Regulation of relaxin signaling helps coordinate structural flexibility, vascular adaptation, reproductive tissue remodeling, and maternal physiological preparation during pregnancy and reproductive transitions.
Relaxin contributes to connective-tissue flexibility, vascular adaptation, and tissue fluid dynamics.
